CRP and diabetes mellitus: However, a recent meta-analysis, which included data from 40 randomized controlled trials in subjects with type 2 diabetes, found significant improvements with GLP-1RAs compared with standard diabetes therapies (including sulfonylureas, insulins, dipeptidyl peptidase-4 inhibitors, thiazolidinediones) and placebo in several clinical biomarkers, including CRP, tumor necrosis factor-alpha, and adiponectin (markers of inflammation) and malondialdehyde (a marker of oxidative stress) [34].